Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metabolex and J&J: Why Biotech's Pipelines Needs Pharma's

This article was originally published in Start Up

Executive Summary

The J&J/Metabolex drug-swap transaction creates significant value for a private company looking to maximize the exit opportunities for its investors. But radical as it appears for the hitherto conservative J&J, the structure allows the alliance to morph comfortably into a very traditional J&J deal: an acquisition. Moreover, while Metabolex is leveraging J&J's pipeline to the benefit of its investors, J&J is leveraging Metabolex's investors to the benefit of its P&L.

You may also be interested in...



After Statins, What Next?

As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.

After Statins, What Next?

As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.

Biotech IPOs: Why Values Will Increase

Acquisitions and crossover investors are just beginning to push up IPO prices for the best biotech offerings, providing the first hints of real competition for shares of new issues.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091288

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel